Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway

Current Medicinal Chemistry

Volumn 20, Issue 33, 2013, Pages 4185-4194

  Li, Wei ^a   Ma, Jiguang ^a   Ma, Qingyong ^a   Li, Bin ^a   Han, Liang ^a   Liu, Jiangbo ^a   Xu, Qinhong ^a   Duan, Wanxing ^a   Yu, Shuo ^a   Wang, Fengfei ^b   Wu, Erxi ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

E cadherin; EMT; Invasion; Metastasis; NF B pathway; Pancreatic cancer; PI 3K Akt pathway; Resveratrol; TGF

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; METASTASIS; PANCREAS CANCER; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CHROMONES; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MATRIX METALLOPROTEINASES; MORPHOLINES; NF-KAPPA B; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STILBENES; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

EID: 84887948346     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990251     Document Type: Article

References (39)

1. Loos, M.; Kleeff, J.; Friess, H.; Buchler, M. W. Surgical treatment of pancreatic cancer. Ann. N. Y. Acad. Sci., 2008, 1138, 169-180.
2. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA. Cancer J. Clin., 2012, 62(1), 10-29.
3. Li, W.; Ma, Q.; Liu, J.; Han, L.; Ma, G.; Liu, H.; Shan, T.; Xie, K.; Wu, E. Hyperglycemia as a mechanism of pancreatic cancer metastasis. Front. Biosci., 2012, 17, 1761-1774.
4. Sarkar, F. H.; Banerjee, S.; Li, Y. Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl. Pharmacol., 2007, 224(3), 326-336.
5. Castellanos, E. H.; Cardin, D. B.; Berlin, J. D. Treatment of earlystage pancreatic cancer. Oncology (Williston Park), 2011, 25(2), 182-189.
6. Campen, C. J.; Dragovich, T.; Baker, A. F. Management strategies in pancreatic cancer. Am. J. Health Syst. Pharm., 2011, 68(7), 573-584.
7. Cheng, Z. X.; Sun, B.; Wang, S. J.; Gao, Y.; Zhang, Y. M.; Zhou, H. X.; Jia, G.; Wang, Y. W.; Kong, R.; Pan, S. H. Nuclear Factor-B-Dependent Epithelial to Mesenchymal Transition Induced by HIF-1α Activation in Pancreatic Cancer Cells under Hypoxic Conditions. PLoS One, 2011, 6(8), e23752.
8. Yilmaz, M.; Christofori, G. Mechanisms of motility in metastasizing cells. Mol. Cancer Res., 2010, 8(5), 629-642.
9. Tsuji, T.; Ibaragi, S.; Hu, G. F. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res., 2009, 69(18), 7135-7139.
10. Kopp, P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur. J. Endocrinol., 1998, 138(6), 619-620.
11. Pirola, L.; Frojdo, S. Resveratrol: one molecule, many targets. IUBMB Life, 2008, 60(5), 323-332.
12. Albani, D.; Polito, L.; Signorini, A.; Forloni, G. Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors, 2010, 36(5), 370-376.
13. Baur, J. A. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech. Ageing Dev., 2010, 131 (4), 261-269.
14. Fulda, S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov. Today, 2010, 15 (17-18), 757-765.
15. Jha, R. K.; Ma, Q.; Sha, H.; Palikhe, M. Emerging role of resveratrol in the treatment of severe acute pancreatitis. Front. Biosci. (Schol Ed), 2010, 2, 168-175.
16. Pervaiz, S.; Holme, A. L. Resveratrol: its biologic targets and functional activity. Antioxid. Redox. Sign., 2009, 11(11), 2851-2897.
17. Wood, L. G.; Wark, P. A.; Garg, M. L. Antioxidant and antiinflammatory effects of resveratrol in airway disease. Antioxid. Redox. Sign., 2010, 13(10), 1535-1548.
18. Wu, J. M.; Hsieh, T. C. Resveratrol: a cardioprotective substance. Ann. N. Y. Acad. Sci., 2011, 1215, 16-21.
19. Bishayee, A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila), 2009, 2(5), 409-418.
20. Tang, F. Y.; Su, Y. C.; Chen, N. C.; Hsieh, H. S.; Chen, K. S. Resveratrol inhibits migration and invasion of human breast-cancer cells. Mol. Nutr. Food Res., 2008, 52(6), 683-691.
21. Brisdelli, F.; D'Andrea, G.; Bozzi, A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr. Drug Metab., 2009, 10(6), 530-546.
22. Kundu, J. K.; Surh, Y. J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett., 2008, 269(2), 243-261.
23. Ding, X. Z.; Adrian, T. E. Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas, 2002, 25(4), e71-76.
24. Harikumar, K. B.; Kunnumakkara, A. B.; Sethi, G.; Diagaradjane, P.; Anand, P.; Pandey, M. K.; Gelovani, J.; Krishnan, S.; Guha, S.; Aggarwal, B. B. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer., 2010, 127(2), 257-268.
25. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25(4), 402-408.
26. Cates, J. M. M.; Byrd, R. H.; Fohn, L. E.; Tatsas, A. D.; Washington, M. K.; Black, C. C. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas, 2009, 38(1), e1.
27. Gilmore, T. Introduction to NF-κB: players, pathways, perspectives. Oncogene, 2006, 25(51), 6680-6684.
28. Lou, C.; Zhang, F.; Yang, M.; Zhao, J.; Zeng, W.; Fang, X.; Zhang, Y.; Zhang, C.; Liang, W. Naringenin decreases invasiveness and metastasis by inhibiting TGF-beta-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One, 2012, 7(12), e50956.
29. Yin, T.; Wang, C.; Liu, T.; Zhao, G.; Zhou, F. Implication of EMT induced by TGF-beta1 in pancreatic cancer. J Huazhong Univ. Sci. Technolog. Med. Sci., 2006, 26(6), 700-702.
30. Renouf, D.; Moore, M. Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev. Anticancer Ther., 2010, 10(4), 529-540.
31. Middleton, G.; Ghaneh, P.; Costello, E.; Greenhalf, W.; Neoptolemos, J. P. New treatment options for advanced pancreatic cancer. Expert Rev. Gastroenterol. Hepatol., 2008, 2(5), 673-696.
32. Azios, N. G.; Dharmawardhane, S. F. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia, 2005, 7(2), 128-140.
33. Kozuki, Y.; Miura, Y.; Yagasaki, K. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett., 2001, 167(2), 151-156.
34. Wu, H.; Liang, X.; Fang, Y.; Qin, X.; Zhang, Y.; Liu, J. Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomed. Pharmacother., 2008, 62(9), 613-621.
35. Wendt, M. K.; Allington, T. M.; Schiemann, W. P. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol., 2009, 5(8), 1145-1168.
36. Wang, H.; Zhang, H.; Tang, L.; Chen, H.; Wu, C.; Zhao, M.; Yang, Y.; Chen, X.; Liu, G. Resveratrol inhibits TGF-1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis. Toxicology, 2012, 303(7), 139-146.
37. Tanno, S.; Mitsuuchi, Y.; Altomare, D. A.; Xiao, G. H.; Testa, J. R. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res., 2001, 61(2), 589-593.
38. Liau, S. S.; Jazag, A.; Whang, E. E. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res., 2006, 66(24), 11613-11622.
39. Teranishi, F.; Takahashi, N.; Gao, N.; Akamo, Y.; Takeyama, H.; Manabe, T.; Okamoto, T. Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Sci., 2009, 100(4), 770-777.